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Synopsis 
Chloride intracellular channel 2 (CLIC2) belongs to a family of intracellular chloride channel 
proteins that can exist in a soluble form. We report here the expression, purification and crystallisation 
of human CLIC2 in two different crystal forms. 
 
Abstract 
The chloride intracellular channel (CLIC) family of proteins are unusual in that they can exist in 
either an integral membrane channel form or a soluble form. Here we report the expression, purification, 
crystallization and preliminary diffraction analysis for CLIC2, one of the least studied members of this 
family. Human CLIC2 was crystallized in two different forms, both in the presence of reduced 
glutathione and both diffracted to better than 1.9 Å resolution. Crystal form A displayed P212121 
symmetry, with unit cell parameters of a = 44.0 Å, b = 74.7 Å and c = 79.8 Å. Crystal form B displayed 
P21 symmetry, with unit cell parameters of a = 36.0 Å, b = 66.9 Å and c = 44.1 Å. Structure 
determination will shed more light on the structure and function of this enigmatic family of proteins. 
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1. Introduction 
The first member of the chloride intracellular channel (CLIC) family was identified based on 
intracellular chloride channel activity and purified by affinity to a chloride channel inhibitor (Landry et 
al., 1993). This led to the identification of a number of homologs that all contain a conserved region of 
approximately 240 residues. Consistent with their original identification as chloride channels, a number 
of family members are able to insert into artificial membranes in vitro and form ion channels with 
varying degrees of anion selectivity. Surprisingly, CLIC family proteins can also exist in a soluble form 
and do not possess any obvious hydrophobic trans-membrane segments, features reminiscent of many 
bacterial pore-forming toxins (Cromer et al., 2002). Based on very weak sequence similarity between 
omega glutathione S-transferase (GST) and the conserved region of CLIC proteins, it was hypothesized 
that, in their soluble form, CLIC proteins adopt the canonical GST fold (Dulhunty et al., 2001). 
Structure determination for both CLIC1 (Harrop et al., 2001) and CLIC4 (Littler et al., 2005, Li et al., 
2006) has confirmed this hypothesis and also revealed that CLIC1 can covalently bind glutathione via a 
conserved cysteine (Cys24) (Harrop et al., 2001), in a similar manner to omega class GSTO1-1 (Board 
et al., 2000). The structure adopted by cytosolic GSTs and soluble CLICs comprises two domains, an N-
terminal mixed α/β thioredoxin-like domain and an all α-helical C-terminal domain. There is good 
evidence that that the N-terminus can translocate across membranes (Tonini et al., 2000), a step in 
channel formation that would require some unfolding of the N-terminal domain. Consistent with this 
concept, oxidation of CLIC1 favours channel formation and leads to an alternative form of soluble 
CLIC1 that is dimeric, with considerable unfolding of the N-terminal domain and formation of an 
intramolecular disulphide between Cys59 and the conserved Cys 24 (Littler et al., 2004).  
CLIC2 is a relatively poorly studied member of the CLIC family. The N-terminal domain of 
CLIC2 lacks the cysteine equivalent to Cys59 of CLIC1 but contains another cysteine Cys33 that, 
together with the conserved Cys30 (equivalent to Cys24 in CLIC1), forms a CXXC motif similar to 
glutaredoxin. Based on these cysteine residue differences, we hypothesized that CLIC2 may undergo 
differential redox regulation and conformational change, relative to CLIC1. To investigate this 
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hypothesis, we have undertaken structural studies of human CLIC2 and report here the production of 
well-diffracting crystals that have enabled the determination of the structure of CLIC2, which will be 
reported elsewhere. 
 
2. Experimental procedures and results 
2.1. Cloning, expression and purification 
CLIC2 was expressed with a His-tagged ubiquitin fused at the N-terminus. Human CLIC2 was 
amplified from the EST clone AI129485 and ligated between the BamHI and PstI sites of the pQE-30 
vector (Qiagen, Clifton Hills, Australia) to produce pQECLIC2 as described previously (Board et al., 
2004). The CLIC2 insert was subcloned as a SacII/HindIII fragment into pHUE (Catanzariti et. al., 
2004) to create a 6His-ubiquitin-CLIC2 fusion protein. This protein was expressed in BL21(DE3) cells 
grown over night in the presence of 0.1mM isopropyl thio-D-galactoside and processed by the methods 
described by Whittington et al. (1999). The recombinant protein was purified by immobilised metal 
affinity chromatography with Ni-agarose as previously described for His-tagged GSTs (Whittington et 
al., 1999). Following dialysis to remove imidazole, the 6His-ubiquitin tag was cleaved by digestion with 
a ubiquitin specific protease (Baker et al., 1994; Cantanzariti et.al., 2004) and both the protease and 
6His-ubiquitin tag were removed by immobilised metal affinity chromatography with Ni-agarose 
(Catanzariti et. al., 2004). The protein was further purified by gel filtration on a Pharmacia fast protein 
liquid chromatography Superose 12 column equilibrated with 50mM Hepes, 10% glycerol, pH 7.0.  
The purified protein was dialysed into 50 mM HEPES pH 7.5 and 100 mM NaCl and 
concentrated to 7.25 mg/ml for crystal form A and 15 mg/ml in 20 mM Tris-HCl pH 7.5, 50 mM NaCl 
for crystal form B. The purified protein was essentially completely monomeric in solution,  as indicated 
by gel-filtration chromatography on a Superdex 75 10/300 chromatography column (GE Biosciences) in 
50 mM sodium phosphate, pH 7.4 and 100 mM sodium chloride (data not shown), and was greater than 
95% pure, as determined by SDS-PAGE. 
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2.2. Crystallisation 
All crystallization experiments were carried out using the hanging-drop vapour-diffusion 
technique using 24-well Limbro tissue culture plates (ICN Inc.) at 19 °C. Drops were formed by mixing 
equal volumes (1 µl) of protein solution and reservoir solution. Two different crystal forms were found 
(Fig. 1) using different batches of purified protein, at different concentrations and with slightly different 
reservoir solutions. For crystal form A, the protein concentration was 7.25 mg/ml and the reservoir 
solution contained 35% - 50% (v/v) PEG 400, 100 mM Tris-HCl pH 8.0 – 9.2 and 5 mM reduced 
glutathione (GSH). Crystals appeared after 2 to 3 days. For crystal form B, the protein concentration was 
15 mg/ml and the reservoir solution contained 30% - 32% (v/v) PEG 400, 100 mM Tris-HCl pH 7.5 and 
5 mM GSH. Crystals appeared after 3 days and were used immediately for X-ray data collection. GSH 
was found to be a necessary ingredient for both crystal forms.  
2.3. Data collection 
Both crystal forms were frozen in the buffer from the crystallisation drop as the concentration of PEG 400 
was sufficient to prevent ice crystal formation. Crystals were mounted in cryo-loops (Hampton Research, 
CA) and transferred directly into a stream of nitrogen gas maintained at 100K. For crystal form A, X-ray 
diffraction data were collected on BioCARS beamline 14-ID-B at the Advanced Photon Source in Chicago, 
USA (Table 1). For crystal form B, X-ray diffraction data were collected in-house using a Rigaku RU200H 
generator equipped with mirror optics (Xenocs) and a MARResearch 345mm imaging plate detector. 
Diffraction data were integrated and scaled using HKL (Otwinowski. & Minor, 1997) for crystal form A and 
MOSFLM (CCP4, 1994) and SCALA (CCP4, 1994) for crystal form B. Data statistics are shown in Table 1. 
Both crystal forms diffracted to better than 1.9 Å resolution. Crystal form A displayed P212121 symmetry, 
with unit cell parameters of a = 44.0 Å, b = 74.7 Å and c = 79.8 Å. Crystal form B displayed P21 symmetry, 
with unit cell parameters of a = 36.0 Å, b = 66.9 Å, c = 44.1 Å and β = 99.9º.   
The structures of CLIC2 in both crystal forms have now been determined by molecular replacement, 
using the published CLIC1 structure (Harrop et al., 2001) as a probe, and have been reported elsewhere 
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(Cromer et al., 2007). The atomic coordinates and structure factors (accession codes 2R4V and 2R5G 
for crystal forms A and B respectively) have been deposited in the Protein Data Bank at the Research 
Collaboratory for Structural Bioinformatics, Rutgers University, New Brunswick, NJ 
(http://www.rcsb.org). These structures will provide further insights into the structure and function of 
this intriguing family of proteins.  
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Table 1 
Crystal data and X-ray diffraction data collection statistics.  
The values in parentheses are for the highest resolution bin. 
Crystal Form A Form B 
Space group P212121 P21 
Cell dimensions (Å) 44.0, 74.7, 79.8 36.0, 66.9, 44.1 
β (º) 90.0 99.9 
Resolution (Å) 1.85 (1.92-1.85) 1.86 (1.95 – 1.86) 
No. of crystals 1 1 
Oscillation range 360° (1° x 360 images) 300° (1° x 300 images) 
Temperature (K) 100 100 
Wavelength (Å) 1.0875 1.54182 
No. of observations 732050 102405 
No. of unique reflections 23144 16303 
Multiplicity 10.5 (4.9) 6.0 (5.3) 
Data completeness (%) 93.9 (62.0) 99.5 (84.3) 
I/σ(I) 31.3 (2.8) 24.2 (5.1) 
Rmerge (%)a 6.8 (30.6) 4.7 (31.5) 
   
aRmerge = ΣhklΣi|Ii  - <I>|/|<I>|, where Ii is the intensity for the ith measurement of an equivalent 
reflection with indices h,k,l.  
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Figure 1. Crystals of CLIC2 in (a) crystal form A and (b) crystal form B. 
(a) 
 
 
(b) 
 
 
